Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunogenicity and protective efficacy on non-adjuvanted CD40-targeting SARS-CoV-2 vaccines in non-human primates.

EBioMedicine·2026
Same author

Immune Profiling Identifies Inflammatory Signatures in Immune Checkpoint Inhibitor-Related Myocarditis.

JACC. CardioOncology·2026
Same author

Divergence in poxvirus-encoded E3-like proteins can dictate poxvirus activation of cellular necroptosis.

Journal of virology·2026
Same author

SARS-CoV-2 mRNA XBB1.5 vaccine immunogenicity in kidney transplant recipients.

Virology journal·2026
Same author

CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteers.

Scientific reports·2026
Same author

Exploring Prejudice Toward Tinder: Two Experiments on the Social Perception of Dating App Users and Online-Formed Couples.

Behavioral sciences (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jun 7, 2026

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Poxvirus vector-based HIV vaccines.

Giuseppe Pantaleo1, Mariano Esteban, Bertram Jacobs

  • 1Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland. Giuseppe.Pantaleo@chuv.ch

Current Opinion in HIV and AIDS
|October 28, 2010
PubMed
Summary

The RV-144 trial demonstrated that a poxvirus-based HIV vaccine can prevent HIV infection, offering new hope and scientific direction for future vaccine development. This marks a significant advancement in the ongoing fight against HIV.

More Related Videos

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Related Experiment Videos

Last Updated: Jun 7, 2026

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • Poxvirus vectors are being explored for HIV vaccine development.
  • Previous HIV vaccine trials, like the Step trial with Ad5-HIV, yielded disappointing results.
  • The RV-144 trial in Thailand investigated a poxvirus-gp120 combination vaccine.

Purpose of the Study:

  • To review the scientific rationale for using poxvirus vectors in HIV vaccines.
  • To describe the immune responses elicited by these vaccines.
  • To update on current clinical trials and novel poxvirus vector development.

Main Methods:

  • Review of scientific literature and clinical trial data.
  • Analysis of immunological profiles from vaccine studies.
  • Evaluation of poxvirus vector-based HIV vaccine candidates.

Main Results:

  • The Step trial (Ad5-HIV) showed no effect on HIV acquisition or viral load.
  • The RV-144 trial (poxvirus-gp120) demonstrated a promising protective effect against HIV infection.
  • This marks the first evidence of an HIV vaccine's efficacy.

Conclusions:

  • The RV-144 trial provides crucial evidence for HIV vaccine efficacy.
  • Results offer a scientific basis for future HIV vaccine research and trial design.
  • Poxvirus vectors remain a key platform for advancing HIV vaccine development.